Nectero Therapeutics Reports Positive Two-Year Safety Data for EAST System in Abdominal Aortic Aneurysm Trial

Key Takeaways

• Nectero Therapeutics completed two-year follow-up data from first-in-human trial of EAST System for abdominal aortic aneurysms
• Results demonstrate safety profile for treating small to medium-sized aneurysms, addressing unmet medical need
• Data presented at Charing Cross 2026 conference supports continued clinical development of the investigational device

---

LONDON - Nectero Therapeutics, a clinical-stage biotechnology company focused on aneurysmal disease treatments, announced positive two-year outcomes from its first-in-human trial of the investigational Nectero EAST® System on April 23, 2026. The results were presented at the prestigious Charing Cross 2026 medical conference.

Addressing Critical Treatment Gap

The EAST System targets small to medium-sized abdominal aortic aneurysms (AAAs), representing a significant unmet medical need in cardiovascular care. Current treatment options for this patient population are limited, with many patients requiring watchful waiting until aneurysms grow large enough for surgical intervention.

Abdominal aortic aneurysms affect approximately 200,000 Americans annually, with rupture carrying mortality rates exceeding 80%. Early intervention for smaller aneurysms could potentially prevent progression to life-threatening complications.

Clinical Trial Significance

The two-year safety and efficacy data marks a crucial milestone for Nectero Therapeutics’ clinical development program. First-in-human trials provide initial evidence of treatment safety and biological activity, informing future larger-scale studies.

The presentation at Charing Cross 2026, a leading international symposium for vascular medicine, underscores the clinical significance of these findings within the medical community.

Market Impact and Future Development

Positive long-term safety data strengthens Nectero’s position in the competitive cardiovascular device market. The company’s focus on earlier-stage aneurysm intervention could differentiate the EAST System from existing surgical approaches.

Successful completion of this trial phase positions Nectero for potential advancement to larger pivotal studies, pending regulatory discussions and additional funding.

The cardiovascular device market for aneurysm treatment represents billions in annual revenue, with growing demand for minimally invasive solutions that can treat patients earlier in disease progression.

---

Frequently Asked Questions

What does this mean for patients with small abdominal aortic aneurysms?

The positive two-year safety data suggests the EAST System could potentially offer earlier treatment options for patients with small to medium aneurysms, who currently have limited therapeutic choices beyond monitoring.

When will the EAST System be available to patients?

The device is still investigational and requires additional clinical trials and regulatory approval. Commercial availability likely remains several years away, pending successful completion of larger pivotal studies.

How does the EAST System compare to current aneurysm treatments?

Current treatments primarily focus on larger aneurysms through surgical repair or endovascular procedures. The EAST System aims to treat smaller aneurysms earlier, potentially preventing progression to more dangerous stages requiring major surgery.